Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: A Gynecologic Oncology Group Study

• Published in: Gynecologic oncology 2011-02, Vol.120 (2), p.185-188
• Main Authors: Covens, Allan L, Filiaci, Virginia, Gersell, Deborah, Lutman, Christopher V, Bonebrake, Albert, Lee, Yi-Chun
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal - adverse effects; Antineoplastic Agents, Hormonal - therapeutic use; Disease-Free Survival; Endometrial Neoplasms - drug therapy; Endometrial Neoplasms - metabolism; Endometrial Neoplasms - pathology; Estradiol - adverse effects; Estradiol - analogs & derivatives; Estradiol - therapeutic use; Female; Hematology, Oncology and Palliative Medicine; Hormonal therapy; Humans; Metastatic endometrial cancer; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local - drug therapy; Neoplasm Recurrence, Local - metabolism; Neoplasm Recurrence, Local - pathology; Obstetrics and Gynecology; Receptors, Estrogen - metabolism; Receptors, Progesterone - metabolism; Recurrent endometrial cancer
• ISSN: 0090-8258; 1095-6859
• DOI: 10.1016/j.ygyno.2010.10.015

Abstract Objectives. To evaluate the activity and toxicity of fulvestrant in advanced, recurrent, or persistent endometrial carcinoma. Methods. Eligible patients with advanced, recurrent or persistent endometrial carcinoma not amenable to curative therapy were treated with fulvestrant at a dose of 250 mg by IM injection every 4 weeks for at least 8 weeks. Therapy was continued until evidence of progressive disease, or adverse effects prohibited further therapy. Response was assessed in patients with at least one target lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.0. Immunohistochemical analysis of tumor tissue (histology or cytology) for estrogen and progesterone receptors was required from the metastatic or recurrent site. Results. Sixty-seven patients were enrolled in this study. Upon review, 14 patients were excluded. In the 22 estrogen receptor (ER) negative patients, no patients demonstrated either a complete or partial response, and 4 (18%) demonstrated stable disease (as best response). In the 31 ER positive patients, 1 (3%), 4 (13%) and 9 (29%) patients demonstrated a complete, partial response, and stable disease (as best response), respectively. The median progression free survival and overall survival in the ER negative patients were 2 and 3 months and in the ER positive patients 10 and 26 months. Treatment was well tolerated, and no patient discontinued therapy due to toxicity. Conclusions. Fulvestrant has minimal activity in advanced, recurrent, or persistent endometrial carcinoma.